We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Ovarian Cancer Biomarker Predicts Therapy Response

By LabMedica International staff writers
Posted on 01 Oct 2018
Despite months of aggressive treatment involving surgery and chemotherapy, about 85% of women with high-grade widespread ovarian cancer will have a recurrence of their disease. More...
This leads to further treatment, but never to a cure. About 15% of patients, however, do not have a recurrence and most of those women remain disease free for years.

An independent prognostic factor has been identified, known as cancer/testis antigen 45 (CT45), which is associated with extended disease-free survival for women with advanced ovarian cancer. Patients with high levels of CT45 in their tumors lived more than seven times as long as patients who lacked sufficient CT45.

Medical scientists at the University of Chicago Medical Center (Chicago, IL, USA) working with their international colleagues studied tissues collected from more than 200 patients with high-grade serous ovarian cancer (HGSOC). They quantitatively analyzed the proteomes of platinum-resistant and -sensitive HGSOC patients from minute amounts of formalin-fixed, paraffin-embedded tumors.

The investigators found no CT45 at all in 82 of those patient samples, but they found high levels in 42 patients, all of whom had much longer disease-free survival. A larger study, using sequence data from The Cancer Genome Atlas, confirmed their initial results, leading to their conclusion that CT45 expression is a novel prognostic indicator for advanced stage high-grade serous ovarian cancer. They also found two peptides from CT45-positive ovarian cancer cells that stimulated a solid immune response against the cancer. T cells collected from a CT45-positive patient with high-grade ovarian cancer were able to kill cancer cells in vitro in a dose-dependent manner.

The authors concluded that the clinical implications from this study could be significant. Expression of CT45 improves the efficacy of platinum-based chemotherapy, and potentially immunotherapy, for patients with advance stage ovarian cancer. CT45 may be particularly relevant to long-term survival. This study highlights the power of clinical cancer proteomics to identify targets for chemo- and immunotherapy, define their mechanisms and contribute to the development of effective cancer therapies.

Matthias Mann, PhD, chairman at the Max-Planck Institute and co-author of the study, said, “Our goal was to find reliable biomarkers that could predict treatment response. Using mass spectrometry, we can identify, for the first time, almost all of the proteins in the tumor tissue of the patients. Our highly sensitive methods now enable us to profile thousands of proteins simultaneously, allowing us to search for the proteins that are critical to the disease by comparing the tissue samples.” The study was published on September 20, 2018 in the journal Cell.

Related Links:
University of Chicago Medical Center


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Serological Pipet Controller
PIPETBOY GENIUS
New
PSA Assay
CanAg PSA EIA
New
Automatic Hematology Analyzer
LABAS F9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.